The results in the univariate Cox analysis were highly consistent presented by the ROR, ADCs (HR 2.83; 95% CI 2.39–3.35), ICIs (HR 2.17; 95% CI 1.72–2.72) and PI3K/AKT/mTOR inhibitors (HR 2.84; 95% CI 2.46–3.28) were associated with a higher odds of reporting for ILD compared to other novel antineoplastic agents. The gene discussed is MTOR; the disease is interstitial lung disease.